Novo Nordisk A/S ADR (NVO): Price and Financial Metrics
GET POWR RATINGS... FREE!
NVO POWR Grades
- NVO scores best on the Quality dimension, with a Quality rank ahead of 99.12% of US stocks.
- NVO's strongest trending metric is Stability; it's been moving up over the last 177 days.
- NVO ranks lowest in Momentum; there it ranks in the 39th percentile.
NVO Stock Summary
- NOVO NORDISK A S's market capitalization of $311,060,464,000 is ahead of 99.56% of US-listed equities.
- With a one year PEG ratio of 797.11, NOVO NORDISK A S is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 96.54% of US stocks.
- NVO's went public 37.1 years ago, making it older than 93.53% of listed US stocks we're tracking.
- If you're looking for stocks that are quantitatively similar to NOVO NORDISK A S, a group of peers worth examining would be ABBV, BABA, LLY, PFE, and MRK.
- Visit NVO's SEC page to see the company's official filings. To visit the company's web site, go to www.novonordisk.com.
NVO Stock Price Chart Interactive Chart >
NVO Price/Volume Stats
| Current price | $138.09 | 52-week high | $144.78 |
| Prev. close | $137.54 | 52-week low | $94.75 |
| Day low | $137.57 | Volume | 1,105,335 |
| Day high | $138.81 | Avg. volume | 1,496,003 |
| 50-day MA | $130.33 | Dividend yield | 0.59% |
| 200-day MA | $113.90 | Market Cap | 312.49B |
Novo Nordisk A/S ADR (NVO) Company Bio
Novo Nordisk A/S is a Danish multinational pharmaceutical company headquartered in Bagsværd, Denmark, with production facilities in nine countries, and affiliates or offices in five countries. Novo Nordisk is controlled by majority shareholder Novo Holdings A/S which holds approximately 25% of its shares and a supermajority (45%) of its voting shares. (Source:Wikipedia)
Latest NVO News From Around the Web
Below are the latest news stories about NOVO NORDISK A S that investors may wish to consider to help them evaluate NVO as an investment opportunity.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your RadarThe Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now. |
Eli Lilly, Novo Nordisk Get a Share-Price Pop From Weight-Loss DrugsEli Lilly rose 33% and Novo Nordisk rose 25% last year behind sales of the first drugs found to cause dramatic weight loss. |
Novartis' (NVS) Unit to Acquire Astellas' Rights of MycamineNovartis' (NVS) generic unit Sandoz is set to acquire rights to the antifungal product Mycamine from Astellas. |
3 Drug Stocks With Promising Pipelines for 2023These 3 drug stocks with promising pipelines are in position to reward investors in 2023 due to multiple factors. |
Novo Nordisk (NVO) Stock Sinks As Market Gains: What You Should KnowIn the latest trading session, Novo Nordisk (NVO) closed at $141.08, marking a -0.01% move from the previous day. |
NVO Price Returns
| 1-mo | 3.40% |
| 3-mo | 26.73% |
| 6-mo | 19.43% |
| 1-year | 46.23% |
| 3-year | 138.15% |
| 5-year | 156.11% |
| YTD | 2.03% |
| 2022 | 22.12% |
| 2021 | 62.55% |
| 2020 | 22.56% |
| 2019 | 27.79% |
| 2018 | -12.54% |
NVO Dividends
| Ex-Dividend Date | Type | Payout Amount | Change | ||||||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Continue Researching NVO
Want to see what other sources are saying about Novo Nordisk A S's financials and stock price? Try the links below:Novo Nordisk A S (NVO) Stock Price | Nasdaq
Novo Nordisk A S (NVO) Stock Quote, History and News - Yahoo Finance
Novo Nordisk A S (NVO) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...